{"id":4214,"date":"2026-11-11T09:00:00","date_gmt":"2026-11-11T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4214"},"modified":"2026-11-11T20:45:25","modified_gmt":"2026-11-12T00:45:25","slug":"china-clears-iaso208-for-clinical-study","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4214","title":{"rendered":"China Clears IASO208 for Clinical Study"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_IASO208_Therapeutic_Indications-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4236\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_IASO208_Therapeutic_Indications-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_IASO208_Therapeutic_Indications-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_IASO208_Therapeutic_Indications-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_IASO208_Therapeutic_Indications-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_IASO_Bio_IASO208_Therapeutic_Indications.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>IASO Bio<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>China IND clearance<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>In vivo CAR T (lentiviral)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>IASO208<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD20<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Relapsed or refractory B-cell non-Hodgkin lymphoma<\/p>\n<h4>Summary<\/h4>\n<p>IASO Bio disclosed November 11 that China cleared the IND for IASO208, a CD20-targeted in-vivo CAR-T program. IND clearance allows a trial; it is not an efficacy determination or marketing approval.<\/p>\n<p>The Chinese company newsroom lists the November 11 announcement. The company previously said the US FDA allowed its IND in September and that 11 patients had been dosed in a China investigator-initiated study, without a controlled efficacy estimate in this disclosure. The company positions the program for relapsed or refractory B-cell non-Hodgkin lymphoma.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> parallel US and China clinical permissions may accelerate learning about direct in-vivo T-cell engineering. Support: both jurisdictions have permitted investigation and early exposure exists. Against: regulatory permissions establish only an acceptable study basis, not clinical benefit.<\/p>\n<p><strong>Interpretation B:<\/strong> manufacturing and systemic vector risks may limit the platform despite speed. Support: durable lentiviral engineering raises insertional and off-target-cell concerns. Against: early company-reported tolerability is encouraging but insufficiently granular. Verify regulator listing, study protocol, vector biodistribution, transduction specificity, cytokine toxicity, insertion-site analyses and durable responses before upgrading. China IIT results are not automatically portable to global registrational trials.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>IASO208 uses a CD20-directed in-vivo CAR-T approach intended to engineer T cells after infusion rather than ex-vivo manufacture. CD20 is expressed on many B-cell lymphomas and normal B cells.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>The China IND clearance is the new event; the US IND clearance in September is prior status.<\/li>\n<li>No controlled efficacy estimate accompanies the disclosure.<\/li>\n<li>IND clearance does not establish clinical benefit.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A parallel-jurisdiction regulatory step for an in-vivo CAR-T program. Clinical value depends on vector biodistribution, safety and durable responses that are not yet disclosed.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: neutral. Confidence in Facts: moderate-high. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IASO Bio disclosed November 11 that China cleared the IND for IASO208, a CD20-targeted in-vivo CAR-T program. IND clearance allows a trial; it is not an efficacy determination or marketing approval.<\/p>\n","protected":false},"author":1,"featured_media":4236,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[775,1439,1440],"class_list":["post-4214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-iaso-bio","tag-iaso208","tag-in-vivo-car-t-2"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4214"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4214\/revisions"}],"predecessor-version":[{"id":4247,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4214\/revisions\/4247"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4236"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}